OK, I read AARP, The Magazine. I am older than 50, and have been reading it for a few years, let’s just leave it at that. (It took me nearly six months to get AARP to stop sending me junk mail life and auto insurance offers. Yes, anything’s possible, but that’s another blog.)
I normally wouldn’t publicly admit all this but for the fact that the current edition (April/May 2012) includes a story “The War On Cancer: More Americans Are Surviving. Here’s Why” that made my inner voice scream, “John, you know you can’t let this go without comment!”
Author Tom Slear sketches out a well-written review for the lay person, nimbly escorting the reader through years of cancer research progress, from President Nixon’s War on Cancer to targeted therapies available today. AARP and Mr. Slear seize on the latest revelations by a Virginia Commonwealth University researcher that more cancer survivors are living longer today and that nearly half die from causes other than cancer. The National Cancer Institute estimates more than 12 million cancer survivors today.
So what’s the problem?
Over five full pages, the author quotes prominent cancer researchers such as Richard Schilsky, MD, of the University of Chicago, with whom my firm Spectrum has worked in the past, and societies such as the American Association for Cancer Research (AACR, a long-time Spectrum client). Readers are made to perceive that it’s but a three-way partnership among academic cancer centers, medical societies and government money that brings the public breakthrough treatments such as Gleevec in 2001.
Mr. Slear credits Gleevec to research “that emanated” from the work of Dr. Brian Druker of the Oregon Health and Science University in Portland.
But Gleevec didn’t just appear thanks alone to academic researchers funded by the government. This practice-changing, life-saving compound was born in the labs of an industry reviled by many and badmouthed by more – pharmaceuticals.
(more…)